From: New somatic BRAF splicing mutation in Langerhans cell histiocytosis
Patient | Gender | Age at diagnosis (years) | Extension (DAS max) | Involved organs | First-line therapy | Response to first-line therapy | Recur-rence | MAPKinases mutationa |
---|---|---|---|---|---|---|---|---|
P1 | F | 1.0 | MS RO+ (5) | Multifocal bone, lymph nodes, hematologic, liver, spleen | VLB-steroid | ADB | No | WT |
P2 | M | 17.5 | SS (1) | Localized bone | Wait and see | _ | No | WT |
P3 | F | 0.8 | MS RO+ (8) | Multifocal bone, skin, lymph nodes, hematologic, spleen | VLB-steroid | ADB | Yes | WT |
P4 | M | 0.5 | SS (1) | Localized bone | VLB-steroid | NAD | No | WT |
P5 | F | 4.9 | SS (1) | Localized bone | Wait and see | _ | No | BRAF c.1511_1517 + 2dup |
P6 | F | 10.2 | SS (0) | Multifocal bone | Wait and see | _ | Yes | BRAF c.1511_1517 + 2dup |
P7 | F | 8.7 | SS (0) | Localized bone | Wait and see | _ | No | WT |
P8 | F | 1.1 | SS (1) | Multifocal bone | VLB-steroid | NAD | No | WT |
P9 | M | 2.8 | SS (4) | Localized bone | VLB-steroid | NAD | No | WT |